Truist Financial Maintains Hims & Hers Health(HIMS.US) With Hold Rating
BofA Securities Maintains Hims & Hers Health(HIMS.US) With Buy Rating, Maintains Target Price $25
Leerink Partners Maintains Hims & Hers Health(HIMS.US) With Hold Rating, Raises Target Price to $26
BofA Securities Maintains Hims & Hers Health(HIMS.US) With Buy Rating, Raises Target Price to $25
Cautious Hold Rating on Hims & Hers Health Amid GLP-1 Supply Uncertainty and Market Volatility
Truist Financial Maintains Hims & Hers Health(HIMS.US) With Hold Rating, Maintains Target Price $23
Hims & Hers Health Analyst Ratings
BofA Securities Maintains Hims & Hers Health(HIMS.US) With Buy Rating, Raises Target Price to $23
Truist Financial Maintains Hims & Hers Health(HIMS.US) With Hold Rating, Announces Target Price $23
Truist Financial Maintains Hims & Hers Health(HIMS.US) With Hold Rating
Analysts Offer Insights on Healthcare Companies: Insmed (INSM), Verona Pharma (VRNA) and Hims & Hers Health (HIMS)
Citi Maintains Hims & Hers Health(HIMS.US) With Hold Rating, Maintains Target Price $20
BofA Securities Maintains Hims & Hers Health(HIMS.US) With Buy Rating, Cuts Target Price to $20
Citi Downgrades Hims & Hers Health(HIMS.US) to Hold Rating, Maintains Target Price $20
Hold Rating on Hims & Hers Health Amid Competitive Threats From Lilly's Zepbound
Needham Initiates Hims & Hers Health(HIMS.US) With Buy Rating, Announces Target Price $24
Hims & Hers Health Analyst Ratings
Analysts Offer Insights on Healthcare Companies: Hims & Hers Health (HIMS) and RxSight (RXST)
BofA Securities Maintains Hims & Hers Health(HIMS.US) With Buy Rating, Maintains Target Price $24
Leerink Partners Maintains Hims & Hers Health(HIMS.US) With Hold Rating, Cuts Target Price to $21